10.52
Intellia Therapeutics Inc stock is traded at $10.52, with a volume of 3.19M.
It is up +3.90% in the last 24 hours and down -22.02% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$10.12
Open:
$10.23
24h Volume:
3.19M
Relative Volume:
0.64
Market Cap:
$1.13B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-1.9197
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
-4.28%
1M Performance:
-22.02%
6M Performance:
-13.56%
1Y Performance:
-54.26%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
NTLA
Intellia Therapeutics Inc
|
10.52 | 1.15B | 45.97M | -508.80M | -382.65M | -5.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Mar-05-25 | Initiated | H.C. Wainwright | Buy |
Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Apr-13-23 | Initiated | Canaccord Genuity | Buy |
Mar-21-23 | Initiated | Bernstein | Outperform |
Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Oct-11-22 | Initiated | Morgan Stanley | Overweight |
Sep-21-22 | Initiated | JP Morgan | Overweight |
Sep-01-22 | Initiated | Citigroup | Sell |
Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
Jun-16-22 | Initiated | BofA Securities | Buy |
Apr-28-22 | Initiated | Credit Suisse | Outperform |
Feb-18-22 | Initiated | William Blair | Outperform |
Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
Jan-31-22 | Initiated | Cowen | Outperform |
Jan-07-22 | Initiated | Piper Sandler | Overweight |
Oct-05-21 | Initiated | Guggenheim | Buy |
Sep-24-21 | Initiated | Stifel | Buy |
Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
Jun-11-21 | Initiated | H.C. Wainwright | Buy |
May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
May-04-21 | Initiated | RBC Capital Mkts | Outperform |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Oct-27-20 | Initiated | Truist | Buy |
Oct-14-20 | Initiated | Wells Fargo | Overweight |
Sep-18-20 | Initiated | Goldman | Buy |
Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jul-09-19 | Initiated | Robert W. Baird | Outperform |
Jun-10-19 | Initiated | ROTH Capital | Neutral |
May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
Oct-29-18 | Initiated | Credit Suisse | Neutral |
Sep-21-18 | Initiated | Raymond James | Mkt Perform |
May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
Nov-01-17 | Reiterated | Jefferies | Buy |
Jun-22-17 | Resumed | Jefferies | Buy |
Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
The Future of Medicine: Investing in Organoid Technology's Biotech Revolution - AInvest
ARK Investment's Confidence in Intellia Therapeutics Drives Analyst Upgrades and Positive Market Sentiment - AInvest
Intellia Therapeutics Inc. Price Targets Raised After ReboundMarket Sentiment Review & Community Consensus Stock Picks - beatles.ru
Intellia (NTLA.O) Sharp Drop: Technical Clues and Market Clusters Point to Pressure - AInvest
Intellia (NTLA.O) Sharp Intraday Drop: Technicals, Order Flow, and Peer Dynamics Signal a Sudden Selloff - AInvest
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
Cathie Wood's ARK Investment Purchases 560K Shares of Intellia Therapeutics - AInvest
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - MSN
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PN - MSN
Is Intellia Therapeutics Inc. stock a smart retirement pickJuly 2025 Trends & Technical Buy Zone Confirmation - newsyoung.net
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer - TipRanks
Upgrade Alert: Intellia Therapeutics' Time to Shine - AInvest
Intellia Therapeutics Inc. Reversal Rally May Surprise BearsJuly 2025 Big Picture & Long-Term Capital Growth Strategies - newsyoung.net
Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade) (NASDAQ:NTLA) - Seeking Alpha
Is Intellia Therapeutics Inc. stock a buy or sellTrade Analysis Summary & Weekly Chart Analysis and Trade Guides - thegnnews.com
Reversal Confirmed Intellia Therapeutics Inc. Stock Rallies Above MAJuly 2025 Decliners & Reliable Breakout Forecasts - newsyoung.net
Guggenheim Sticks to Its Buy Rating for Intellia Therapeutics (NTLA) - The Globe and Mail
Will Intellia Therapeutics Inc. outperform small cap indexesTrade Entry Report & Fast Moving Stock Trade Plans - mustnews.co.kr
Intellia Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year By Investing.com - Investing.com Australia
Intellia Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year - Investing.com
Guggenheim Maintains Buy Rating for Intellia Therapeutics with $14 Price Target - AInvest
Intellia Therapeutics’ Earnings Call Highlights Progress and Challenges - The Globe and Mail
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game-Changer? - TipRanks
Guggenheim Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $14 - 富途牛牛
Intellia Therapeutics stock price target slashed by Guggenheim to $14 - Investing.com Nigeria
Why Intellia Therapeutics Inc. stock attracts strong analyst attentionEMA/SMA Crossover Stock List - sisaissue.com
Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - Yahoo Finance
Intellia slides after safety concern for Regeneron-partnered gene editing therapy - MSN
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Intellia Therapeutics: Chardan Capital Keeps Buy Rating, Cuts PT to $60 - AInvest
Will Intellia Therapeutics Inc. Benefit From Broader Market BounceReal Trader Watchlist of Hot Stocks Released - beatles.ru
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript - MSN
Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates - MSN
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - MSN
Citi Maintains Hold Rating on Intellia Therapeutics with $12 Price Target - AInvest
Intellia Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - 富途牛牛
Intellia Therapeutics Surpasses Q2 Earnings and Revenue Expectations - AInvest
Wells Fargo Sticks to Their Buy Rating for Intellia Therapeutics (NTLA) - The Globe and Mail
Intellia Therapeutics Reports Q2 2025 Progress and Financials - The Globe and Mail
Wells Fargo Maintains Overweight on Intellia, PT Down to $45 - AInvest
Intellia Therapeutics stock price target lowered to $45 by Wells Fargo - Investing.com Canada
Leerink Partners lowers Intellia Therapeutics stock price target to $41 By Investing.com - Investing.com Canada
Intellia: HC Wainwright Keeps Buy Rating, Lowers PT to $25 from $30. - AInvest
Gene-Editing's Quiet Revolution: Why Intellia Therapeutics Could Redefine Rare Disease Investing - AInvest
INTELLIA THERAPEUTICS, INC. (NTLA) - MSN
Intellia (NTLA) Q2 Revenue Jumps 106% - AOL.com
Intellia Therapeutics' NTLA-2001 in Phase III Development for ATTR-CM: A Promising CRISPR/Cas9 Therapy - AInvest
Intellia Therapeutics Inc (NTLA) Q2 2025 Earnings Call Highlights: Strategic Advancements and Financial Resilience - GuruFocus
Intellia Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Intellia Therapeutics' Momentum in ATTR-CM and HAE Trials: A Catalyst-Driven Path to First-Time Commercial Success - AInvest
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):